A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratorios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane 0,02mg + 0,075mg (Schering Do Brasil Quimica E Farmaceutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers

Trial Profile

A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratorios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane 0,02mg + 0,075mg (Schering Do Brasil Quimica E Farmaceutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2011

At a glance

  • Drugs Ethinylestradiol/gestodene (Primary)
  • Indications Pregnancy
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Feb 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top